{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:56:49Z","timestamp":1784973409504,"version":"3.55.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Pharmacologic interventions for addressing social impairments in autism spectrum disorder (ASD) are lacking. Proton magnetic resonance spectroscopy (1H-MRS) studies in individuals with ASD have documented altered glutamate levels in the pregenual anterior cingulate cortex (pgACC).<\/jats:p><\/jats:sec>Objectives<\/jats:title>To evaluate the safety and efficacy of memantine for treating social impairments in youths with ASD and to explore pgACC glutamate levels as a potential biomarker for treatment response.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This 12-week, placebo-controlled, double-blind, parallel-design randomized clinical trial was conducted between January 20, 2015, and July 11, 2018. The study population comprised youths aged 8 to 17 years with ASD without intellectual disability (IQ\u226585) recruited from ambulatory psychiatry clinics at an academic institution. Age- and sex-matched healthy control participants provided reference data for pgACC glutamate levels. Data analysis was conducted between January 7, 2020, and December 19, 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants with ASD were randomized to memantine or placebo, with dose titration up to 20 mg\/d. 1H-MRS scans were acquired to assess pgACC glutamate levels.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Response was defined a priori as (1) a 25% or greater reduction in informant-rated Social Responsiveness Scale\u2013Second Edition total scores and (2) a clinician-rated Clinical Global Impression\u2013Improvement subscale (anchored for ASD) score of 2 or less. The association between pgACC glutamate levels and treatment response was explored using receiver operating characteristic (ROC) curve analysis.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 42 youths with ASD who initiated treatment (mean [SD] age, 13.2 [2.6] years; 32 males [76.2%]). Of these youths, 35 were included in the intention-to-treat efficacy analysis (n\u2009=\u200916 treated with memantine and 19 with placebo), and 33 completed the trial (n\u2009=\u200916 treated with memantine and 17 with placebo). Significantly more memantine-treated participants met the response criteria compared with placebo-treated participants (9 of 16 [56.2%] vs 4 of 19 [21.0%]; odds ratio, 4.8 [95% CI, 1.1-21.2]; P<\/jats:italic>\u2009=\u2009.03). Memantine was well tolerated and did not have significantly more adverse events compared with placebo. Mean (SD) pgACC glutamate levels were significantly higher in youths with ASD vs healthy control participants (95.5 [14.6] IU vs 76.6 [17.7] IU; standardized mean difference, \u22121.2 [95% CI, \u22121.8 to \u22120.6]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Abnormally elevated pgACC glutamate levels (\u22651 SD above that of healthy control participants) were observed in 20 of 37 participants (54.0%) with ASD and were associated with more treatment responders to memantine than placebo (8 of 10 [80.0%] vs 2 of 10 [20.0%]; odds ratio, 16.0 [95% CI, 1.8-143.2]; P<\/jats:italic>\u2009=\u2009.007). ROC curve analysis indicated that pgACC glutamate levels were highly efficient at identifying treatment responders.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this trial, memantine was well tolerated and significantly improved social impairments in youths with ASD. Elevated pgACC glutamate levels were associated with a favorable treatment response, supporting their potential as a biomarker for assessing memantine efficacy in individuals with ASD.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01972074<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.34927","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:01:08Z","timestamp":1759330868000},"page":"e2534927","source":"Crossref","is-referenced-by-count":6,"title":["Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder"],"prefix":"10.1001","volume":"8","author":[{"given":"Gagan","family":"Joshi","sequence":"first","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"G\u00f6nenc","sequence":"additional","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"DiSalvo","sequence":"additional","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Faraone","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Upstate Medical University, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga Atilla","family":"Ceranoglu","sequence":"additional","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Yule","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Uchida","sequence":"additional","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Lurie Center for Autism, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, Boston"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"2","key":"zoi250974r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7202a1","article-title":"Prevalence and characteristics of autism spectrum disorder among children aged 8 years\u2014Autism and Developmental Disabilities Monitoring Network, 11 sites, United States.","volume":"72","author":"Maenner","year":"2023","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"zoi250974r2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children.","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res"},{"issue":"4","key":"zoi250974r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003495.pub3","article-title":"Intravenous secretin for autism spectrum disorders (ASD).","volume":"2012","author":"Williams","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"zoi250974r4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.","volume":"21","author":"Remington","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"zoi250974r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004677.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).","volume":"2013","author":"Williams","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"zoi250974r6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJMoa2103583","article-title":"Intranasal oxytocin in children and adolescents with autism spectrum disorder.","volume":"385","author":"Sikich","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi250974r7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41380-018-0097-2","article-title":"Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.","volume":"25","author":"Yamasue","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"4S","key":"zoi250974r8","doi-asserted-by":"publisher","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: review of physiology and pathology.","volume":"130","author":"Meldrum","year":"2000","journal-title":"J Nutr"},{"issue":"10","key":"zoi250974r9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025340","article-title":"Alteration of plasma glutamate and glutamine levels in children with high-functioning autism.","volume":"6","author":"Shimmura","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"zoi250974r10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0887-8994(96)00218-4","article-title":"High levels of cerebrospinal fluid glutamate in Rett syndrome.","volume":"15","author":"Lappalainen","year":"1996","journal-title":"Pediatr Neurol"},{"issue":"8","key":"zoi250974r11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0006-3223(02)01430-0","article-title":"Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices.","volume":"52","author":"Fatemi","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"3","key":"zoi250974r12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/sj.mp.4000979","article-title":"Linkage and association of the glutamate receptor 6 gene with autism.","volume":"7","author":"Jamain","year":"2002","journal-title":"Mol Psychiatry"},{"issue":"4","key":"zoi250974r13","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.40.4.e42","article-title":"The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism.","volume":"40","author":"Serajee","year":"2003","journal-title":"J Med Genet"},{"issue":"4","key":"zoi250974r14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1176\/appi.ajp.161.4.662","article-title":"Linkage and association of the mitochondrial aspartate\/glutamate carrier SLC25A12 gene with autism.","volume":"161","author":"Ramoz","year":"2004","journal-title":"Am J Psychiatry"},{"key":"zoi250974r15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnmol.2016.00014","article-title":"A comprehensive review of the (1)H-MRS metabolite spectrum in autism spectrum disorder.","volume":"9","author":"Ford","year":"2016","journal-title":"Front Mol Neurosci"},{"key":"zoi250974r16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.pnpbp.2018.09.010","article-title":"The contribution of [1H] magnetic resonance spectroscopy to the study of excitation-inhibition in autism.","volume":"89","author":"Ajram","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"zoi250974r17","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/hbm.20667","article-title":"Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model.","volume":"30","author":"Palomero-Gallagher","year":"2009","journal-title":"Hum Brain Mapp"},{"issue":"31","key":"zoi250974r18","doi-asserted-by":"publisher","first-page":"12698","DOI":"10.1523\/JNEUROSCI.1758-13.2013","article-title":"Systematic regional variations of GABA, glutamine, and glutamate concentrations follow receptor fingerprints of human cingulate cortex.","volume":"33","author":"Dou","year":"2013","journal-title":"J Neurosci"},{"issue":"6","key":"zoi250974r19","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/cercor\/bhy124","article-title":"Human pregenual anterior cingulate cortex: structural, functional, and connectional heterogeneity.","volume":"29","author":"Palomero-Gallagher","year":"2019","journal-title":"Cereb Cortex"},{"issue":"7","key":"zoi250974r20","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/s41380-023-02079-y","article-title":"Neurometabolite levels in the brains of patients with autism spectrum disorders: a meta-analysis of proton magnetic resonance spectroscopy studies (N?=?1501).","volume":"28","author":"Du","year":"2023","journal-title":"Mol Psychiatry"},{"key":"zoi250974r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105728","article-title":"Neurometabolite differences in autism as assessed with magnetic resonance spectroscopy: a systematic review and meta-analysis.","volume":"162","author":"Thomson","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"zoi250974r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038786","article-title":"Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI.","volume":"7","author":"Bejjani","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"zoi250974r23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.rasd.2012.12.005","article-title":"Blood and brain glutamate levels in children with autistic disorder.","volume":"7","author":"Hassan","year":"2013","journal-title":"Res Autism Spectr Disord"},{"issue":"12","key":"zoi250974r24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/npp.2016.260","article-title":"Fronto-striatal glutamate in autism spectrum disorder and obsessive compulsive disorder.","volume":"42","author":"Naaijen","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"zoi250974r25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00406-012-0369-9","article-title":"Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T.","volume":"263","author":"Joshi","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"zoi250974r26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial.","volume":"31","author":"Belsito","year":"2001","journal-title":"J Autism Dev Disord"},{"issue":"6","key":"zoi250974r27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.","volume":"40","author":"King","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"zoi250974r28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"key":"zoi250974r29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder.","volume":"7","author":"Wink","year":"2016","journal-title":"Mol Autism"},{"issue":"3","key":"zoi250974r30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0004867416652735","article-title":"A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder.","volume":"51","author":"Dean","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"zoi250974r31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.","volume":"16","author":"Owley","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"zoi250974r32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders.","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"zoi250974r33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/0883073807302611","article-title":"Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.","volume":"22","author":"Chez","year":"2007","journal-title":"J Child Neurol"},{"issue":"5","key":"zoi250974r34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2015.0146","article-title":"Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension.","volume":"27","author":"Aman","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"zoi250974r35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/JCP.0000000000000499","article-title":"A prospective open-label trial of memantine hydrochloride for the treatment of social deficits in intellectually capable adults with autism spectrum disorder.","volume":"36","author":"Joshi","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"zoi250974r38","first-page":"839","article-title":"Clinical Global Impression (CGI) scale.","volume":"21","author":"National Institute of Mental Health","year":"1985","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"zoi250974r40","first-page":"485","article-title":"The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects.","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"issue":"9","key":"zoi250974r41","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/01.chi.0000220854.79144.e7","article-title":"Children\u2019s Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.","volume":"45","author":"Scahill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"zoi250974r46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/mrm.22540","article-title":"Comparison of spectral fitting methods for overlapping J-coupled metabolite resonances.","volume":"64","author":"Gonenc","year":"2010","journal-title":"Magn Reson Med"},{"issue":"5","key":"zoi250974r47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems.","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"key":"zoi250974r36","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi250974r37","volume-title":"Social Responsiveness Scale\u2013Second Edition (SRS-2) Manual","author":"Constantino","year":"2012"},{"key":"zoi250974r39","volume-title":"Kiddie-Schedule for Affective Disorders and Schizophrenia\u2013Epidemiologic Version (K-SADS-E)","author":"Orvaschel","year":"1995"},{"key":"zoi250974r42","volume-title":"ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"1998"},{"key":"zoi250974r43","volume-title":"Children\u2019s Depression Rating Scale, Revised (CDRS-R)","author":"Poznanski","year":"1996"},{"key":"zoi250974r44","volume-title":"Child and Adolescent Symptom Inventory-5 Manual","author":"Gadow","year":"2013"},{"key":"zoi250974r45","first-page":"32","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","edition":"4th ed"},{"key":"zoi250974r48","volume-title":"Stata Statistical Software: Release 19","author":"StataCorp","year":"2024"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839518\/joshi_2025_oi_250974_1758732898.90739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:01:11Z","timestamp":1759330871000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839518"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34927","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}